Diagnosis and Complication Risk Assessment of Pancreatic Diabetes within Normal Value Ranges of Leuc
- Summary
- This patent can use for daily complication risk Assessment of all diabetic patients and save lifes, suffering from the diabetic complications at all around the world. it is more important method than Hemoglobin A1c. Because all diabetic complications can monitorizing using one marker (procalcitonin) in 24 hours period. New technology of insulin pump system or traditional diabetes mellitus therapy need this invention for proper diabetic complication (retinopathy, nephropathy,neuropathy) treatment
- Detailed Technology Description
- This method use rapid or Automatic test device for procalcitonin blood levels
- Type of Cooperation
- License agreement
- Supplementary Information
- Inventor: Chonge Chen | Cleph. Sturt. Keklam | chuxian Wu
Priority Number: CN100572554C
IPC Current: C12Q000168
Assignee Applicant: The Chinese University of Hong Kong
Title: Risk estimution for diabetic to suffer from diabetic renopathy or blood-lipid imbalance | Evaluation diabetes patients suffer from diabetic nephropathy, or dyslipidemia disorder risk of
Usefulness: Risk estimution for diabetic to suffer from diabetic renopathy or blood-lipid imbalance | Evaluation diabetes patients suffer from diabetic nephropathy, or dyslipidemia disorder risk of
Novelty: Risk estimation for diabetic to suffer from diabetic renopathy or blood-lipid imbalance
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- Application No.
- EP20120154587
- Coverage Areas
- EPO designated contracting states
- Patent Information
- Status: Patent Application
- Others
- Price: negotiable
- Country/Region
- Turkiye
For more information, please click Here
